10-K: Integer Holdings Reports 8% Sales Growth, Net Income Dips

Integer Holdings Corporation announced an 8% increase in total sales to $1.854 billion for fiscal year 2025, though net income decreased by 15.1% due to a significant debt conversion expense.

Summary

• Total sales for 2025 increased 8% to $1.854 billion, up from $1.717 billion in 2024, driven by new product ramps in targeted high-growth markets, higher demand across the base business, and contributions from recent acquisitions.
• Gross profit increased 9% to $500.4 million in 2025, with gross margin improving to 27.0% from 26.7% in 2024, primarily from higher sales volume leverage and supply chain efficiencies.
• Income from continuing operations decreased 15.1% to $102.8 million ($2.89 diluted EPS) in 2025, from $121.1 million ($3.40 diluted EPS) in 2024.
• The decrease in net income was primarily due to a $46.7 million debt conversion inducement expense and higher operating expenses.
• Cardio & Vascular (C&V) sales grew 16.6% to $1.107 billion, driven by strong growth from new product ramps in electrophysiology, contributions from acquisitions, and strong demand in neurovascular.
• Cardiac Rhythm Management & Neuromodulation (CRM&N) sales increased 1.2% to $668.8 million, growing at market, but offset by the planned decline of an early spinal cord stimulation neuromodulation customer.
• Other Markets sales decreased 26.9% to $77.8 million, primarily due to the planned multi-year exit from the Portable Medical market, expected to complete in 2026.
• The company completed three tuck-in acquisitions in 2025: Precision Coating LLC (January 7), VSi Parylene (February 28), and Biocoat Incorporated (December 4), adding specialized coating technologies.
• Firm backlog orders at December 31, 2025, were approximately $675 million, with the majority expected to ship within one year.
• Three customers (Abbott Laboratories, Boston Scientific, Medtronic) each accounted for over 10% of total sales in 2025, collectively representing 49% of total sales.
• Cash and cash equivalents decreased by $29.4 million to $17.2 million at year-end 2025.
• Total debt outstanding at December 31, 2025, was $1.2 billion.
• The company issued $1.0 billion in 1.875% Convertible Senior Notes due 2030 in March 2025, using proceeds to exchange $383.7 million of 2.125% Convertible Senior Notes due 2028 and pay down other debt.
• Repurchased 698,356 shares of common stock for $50.0 million in 2025 under a $200 million share repurchase program, with $150 million remaining available.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While the company achieved solid sales growth and strategic acquisitions, the significant one-time debt conversion expense heavily impacted net income, and the 2026 sales outlook is tempered by new product adoption challenges. The underlying business growth and strategic positioning are positive, but the financial impact of the debt transaction and future product adoption concerns warrant caution.

Positives

• Total sales increased 8% to $1.854 billion in 2025, demonstrating strong top-line growth.
• Gross profit increased 9% to $500.4 million, with gross margin improving to 27.0% from 26.7%, indicating operational efficiencies.
• Cardio & Vascular sales showed robust growth of 16.6%, driven by new product ramps and strategic acquisitions.
• Successfully executed a tuck-in acquisition strategy with three acquisitions in 2025 (Precision Coating, VSi Parylene, Biocoat), enhancing service offerings and capabilities.
• Firm backlog orders of approximately $675 million at year-end 2025 provide a strong revenue base for the near future.
• Interest expense decreased by $13.2 million, primarily due to lower weighted average interest rates and a shift to lower fixed-rate debt.
• Increased fixed-rate borrowings to approximately 92% of total debt, significantly reducing exposure to interest rate risk.
• Management's assessment confirmed effective internal control over financial reporting as of December 31, 2025.

Negatives

• Income from continuing operations decreased 15.1% to $102.8 million in 2025, and diluted EPS from continuing operations decreased 15.0% to $2.89.
• A significant 'Other loss, net' of $53.2 million was recorded in 2025, primarily due to a $46.7 million debt conversion inducement expense, which is a non-recurring item.
• Sales in 'Other Markets' decreased 26.9% due to the planned multi-year exit from the Portable Medical market.
• Cash and cash equivalents decreased by $29.4 million in 2025, indicating a net cash outflow.
• Sales growth in 2026 is expected to be impacted by lower than anticipated market adoption for three new products, which management believes is 'highly unusual'.
• Selling, general and administrative (SG&A) expenses increased by $26.5 million (14.3%) in 2025, partly due to leadership transition costs and ERP implementation.
• Restructuring and other charges increased by $5.7 million (47.1%) in 2025.
• High dependence on three major customers (Abbott, Boston Scientific, Medtronic) for 49% of total sales, posing a concentration risk.
• The company is currently experiencing securities class action litigation, which could result in substantial costs and divert management's attention.

Risks

• Heavy dependence on a limited number of customers (top three accounted for 49% of 2025 sales); reductions in demand or loss of any significant customer could materially adversely affect financial condition and results of operations.
• Subject to pricing pressures from customers and contractual pricing constraints, which could harm operating results and financial condition.
• Reliance on third-party suppliers for raw materials, key products, subcomponents, and services; unavailability or increased prices could adversely affect results.
• Supply and price of raw materials (e.g., platinum, stainless steel, gold) susceptible to fluctuations due to transportation issues, government regulations, geopolitical conditions (Ukraine, Middle East, China/Taiwan tensions), tariffs, and worldwide economic conditions.
• Inflationary pressures and macroeconomic conditions could increase overall cost structure (interest rates, capital costs, shipping, labor, exchange rates).
• Shipping risks, including container shortages, blocked shipping lanes, and port backlogs, affecting third-party suppliers.
• Increased costs and expenses from existing and potential future U.S. and foreign legislation, regulations, trade agreements, tariffs, trade wars, and import restrictions.
• Inability to match manufacturing capacity with demand for products, leading to unfulfilled orders or fixed costs from excess capacity.
• Interruptions of manufacturing operations (e.g., weather, natural disaster, war, civil unrest, utility disruptions, pandemics, labor shortages) could delay production and adversely affect operations.
• Inability to attract, train, and retain a sufficient number of qualified associates, especially in technology and engineering, due to aggressive competition and high attrition.
• Quality problems with products could result in warranty claims, additional costs, harm to reputation, and erosion of competitive advantage.
• Operations are subject to cyber-attacks and other information technology disruptions (hackers, malware, employee error, natural disasters, hardware/software failures, power fluctuations) that could lead to data loss, business interruption, litigation, regulatory sanctions, and reputational harm.
• Emerging technologies like generative AI may be used by malicious actors to identify vulnerabilities or strengthen social engineering, increasing the threat landscape.
• Adoption or use of AI tools by the company, customers, suppliers, and third-party vendors may inadvertently introduce new vulnerabilities or expose data.
• Increasingly demanding legal and regulatory environment surrounding information security and privacy (HIPAA, HITECH, California Privacy Rights Act, GDPR), with potential for material fines or litigation for noncompliance.
• Global climate change and related emphasis on ESG matters by various stakeholders could negatively affect business or stock price, requiring additional investments and increasing operating costs.
• Dependence upon senior management team and key technical personnel; loss of any could significantly harm the company.
• Consolidation in the healthcare industry could result in greater competition, pricing pressures, and reduced revenues.
• Inability to successfully market current or future products, or slower market growth (especially in cardiac rhythm management, neuromodulation, and cardio and vascular markets), could adversely affect revenues.
• Risk that products will lose widespread market acceptance or that new products and technologies may not be rapidly accepted due to regulatory clearance, clinical practice patterns, reimbursement uncertainty, or superior competitor products.
• Customers in-sourcing or dual sourcing production, which could cause operating results to suffer.
• Inability to respond to changes in technology, making products obsolete or less competitive, potentially leading to loss of customers and lower revenues.
• Product development efforts affected by ability to anticipate customer needs, develop/acquire new technologies (including AI), secure intellectual property, and manufacture cost-effectively.
• New products may materially and adversely impact sales of existing products.
• Inability to successfully identify, make, and integrate acquisitions to expand and develop the business.
• Difficulties in integrating acquired businesses (operational, technological, personnel challenges, loss of customers/suppliers, IT incompatibility) could divert management attention and harm results.
• Operating results may fluctuate, making forecasting difficult and leading to stock price volatility and potential litigation.
• Inability to guarantee common stock repurchases or that the share repurchase program will enhance long-term stockholder value; repurchases could increase volatility or diminish cash reserves.
• Activist shareholders could negatively impact business, cause disruptions, and divert management attention.
• Significant indebtedness ($1.2 billion at Dec 31, 2025) could adversely affect operations, financial condition, and cash flows if financial covenants are not met or access to capital markets is interrupted.
• Conditional conversion features of 2028 and 2030 Convertible Notes could adversely affect financial condition and operating results, requiring cash settlement or repurchase.
• Transactions relating to Convertible Notes may affect the market price of common stock, including dilution from conversion.
• Counterparty risk with respect to capped call transactions.
• International operations (47% of 2025 sales) subject to risks: changes in foreign economic conditions/regulations, exchange controls, currency restrictions, foreign currency exchange rates, local product preferences, collection delays, intellectual property protection, trade protection measures, workforce instability, natural disasters, political/economic instability, transportation delays, and complex tax/cash management issues.
• Exposure to higher security risks in some international locations.
• Complex international tax profile and potential increases/variability in effective tax rate due to mix of income, acquisitions, settlements, tax law changes (e.g., OBBA, OECD Pillar Two Global Minimum Tax).
• Inability to realize the full value of intangible assets ($1.9 billion at Dec 31, 2025), increasing impairment risk.
• Regulatory issues (product complaints, recalls, audits) could harm ability to produce/supply products or bring new products to market.
• Potential product liability claims (one-off or class action) from product failures, misuse, malfunction, or design flaws, leading to significant litigation costs, damages, and reputational harm.
• Inability to protect intellectual property and proprietary rights (patents, licenses, trade secrets) from misappropriation, circumvention, or invalidation, leading to loss of competitive advantage.
• Subject to intellectual property claims from third parties, which could be costly, time-consuming, and divert management attention.
• Failure to comply with customer-driven policies and standards and third-party certification requirements could adversely affect business and reputation.
• Inability to obtain or loss of licenses from third parties for new technologies could impair ability to design/manufacture new products.
• Subject to environmental regulations (manufacturing, transportation, storage, use/disposal of hazardous materials); historical operations may require future clean-up expenditures.
• International operations expose to legal and regulatory risks (e.g., U.S. Foreign Corrupt Practices Act, anti-corruption laws), leading to government scrutiny, sanctions, and liabilities.
• Healthcare industry is highly regulated and subject to political, economic, and regulatory changes (e.g., EU-MDR, FDA, U.S. healthcare reform) that could increase compliance costs and force product modification/pricing changes.
• Business indirectly subject to healthcare industry third-party coverage and reimbursement and cost containment measures, potentially reducing sales.

Future Outlook

The company expects sales growth in 2026 to be impacted by lower than anticipated market adoption for three new products. Portable Medical sales are projected to wind down with the final market exit occurring in 2026. Capital expenditures for 2026 are estimated to be between $95 million and $105 million, focusing on manufacturing facility upgrades, equipment for productivity initiatives, and IT systems. The company believes its projected cash flows, available cash, and borrowing capacity are sufficient to meet working capital, debt service, and capital expenditure requirements for the next twelve months.

Management Comments

• "Integer has evolved our portfolio strategy to focus on higher growth medtech markets where we possess differentiated capabilities."
• "Integer continues to execute a tuck-in acquisition strategy that has added capabilities, leading brands and complementary technologies, increased customer penetration, and enhanced scale in our targeted growth markets."
• "We believe we are well-positioned within the medical device market and that there is a robust pipeline of opportunities to pursue."
• "We have expanded our medical device capabilities and are excited about opportunities to partner with customers to drive innovation."
• "We believe we have the scale and global presence, supported by world-class engineering, manufacturing, and quality capabilities, to capture these opportunities, drive sales growth, and expand margins over the long-term."
• "In 2026, we expect sales growth to be impacted by lower sales related to three new products due to lower than anticipated market adoption. We believe the magnitude of these changes on multiple products at the same time is highly unusual."
• "Our mission is to advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation."

Industry Context

StockSavvy.ai notes that Integer Holdings Corporation operates in the highly fragmented but consolidating medical device contract development and manufacturing (CDMO) industry. The company's strategic focus on higher-growth medtech markets like Cardio & Vascular, Neuromodulation, and Cardiac Rhythm Management aligns with broader industry trends towards specialized, high-value medical technologies. The continued tuck-in acquisition strategy, exemplified by the 2025 acquisitions of Precision Coating, VSi Parylene, and Biocoat, reflects the industry's drive for enhanced capabilities and comprehensive solutions to meet the evolving needs of large OEM customers who seek broad product capabilities and manufacturing scale. The dependence on a few large multinational OEMs (Abbott, Boston Scientific, Medtronic) is common in this sector, but also highlights customer concentration risk. The mention of increased competition and pricing pressure due to industry consolidation is a key trend impacting CDMOs.

Management Changes

Corporate Governance

Legal Proceedings

• On December 10, 2025, a putative class action lawsuit, 'West Palm Beach Firefighters Pension Fund v. Integer Holdings Corporation, et al.', was filed in the United States District Court for the Southern District of New York, alleging violations of securities laws in the company's public disclosures. The company denies wrongdoing and intends to vigorously defend itself.

Stakeholder Impact

• Shareholders: Potential for dilution from convertible notes conversion, stock price volatility, impact of share repurchase program, and ongoing securities class action litigation.
• Employees: Continued focus on human capital, leadership development, competitive pay/benefits, inclusion, and non-discrimination. Potential for termination benefits due to restructuring and manufacturing alignment initiatives.
• Customers: Continued focus on customer success, impactful innovation, and operational excellence. Risk of reduced demand or loss of significant customers, and pricing pressures.
• Suppliers: Dependence on a limited number of suppliers for critical raw materials, exposing to supply chain disruptions and price fluctuations.
• Creditors: Significant indebtedness ($1.2 billion) and compliance with financial covenants under debt agreements. Conditional conversion features of convertible notes could affect liquidity.

Next Steps

• Complete the wind-down of Portable Medical sales and market exit in 2026.
• Continue Global Manufacturing Alignment initiative, expected to be substantially complete by the end of 2035.
• Complete Research and Product Development Alignment initiative, expected to be substantially complete by the end of 2026.
• Complete 2022 Manufacturing Alignment to Support Growth (MASG) initiatives, expected to be substantially complete by the end of 2026.
• Expected capital expenditures of $95 million to $105 million in 2026 for manufacturing facility upgrades, equipment to support productivity initiatives, and information technology systems.
• Final settlement of the $50.0 million accelerated share repurchase agreement scheduled for the first fiscal quarter ending April 3, 2026.
• Respond to the putative class action lawsuit filed on December 10, 2025.
• Comply with EU-MDR deadlines: Class III custom-made implantable devices by May 26, 2026; Class III devices and some Class IIb implantable devices by end of 2027; remaining Class II devices by end of 2028.

Key Dates

Recommendation

While Integer Holdings Corporation demonstrated strong top-line growth and strategic execution through acquisitions, the substantial one-time debt conversion inducement expense significantly impacted net income and diluted EPS for 2025. The tempered sales outlook for 2026 due to new product adoption challenges, coupled with ongoing litigation and customer concentration risks, suggests a period of uncertainty. However, the company's strong market position, improved gross margin, and proactive debt management (increasing fixed-rate debt) provide a stable foundation. A 'Hold' recommendation is appropriate as investors should monitor the resolution of the legal proceedings, the success of new product adoption, and the integration of recent acquisitions before making further investment decisions.

Keywords

Medical Device Manufacturing, CDMO, Cardio & Vascular, Neuromodulation, Cardiac Rhythm Management, SEC Filing, Annual Report, 10-K, Financial Results, Acquisitions, Supply Chain, Cybersecurity, Intellectual Property, Regulatory Compliance, Share Repurchase, Convertible Notes, ESG, Healthcare Industry